Repligen | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
Agilent USD 899M 18M 2025-01
Align Technology USD 696.94M 15.17M 2024-12
Bio Techne USD 196.58M 8.66M 2024-12
BioMarin Pharmaceutical USD 611.17M 53.89M 2024-12
Bristol-Myers Squibb USD 9.13B 94M 2024-12
Bruker USD 493.3M 74.5M 2024-12
Charles River Laboratories USD 319.68M 48.09M 2024-12
Danaher USD 3.89B 489M 2024-12
Dentsply International USD 455M 40M 2024-12
Exact Sciences USD 429.29M 83.29M 2024-12
General Electric USD 3.63B 702M 2024-12
Henry Schein USD 993M 0 2024-12
Illumina USD 728M 17M 2024-12
IQVIA Holdings USD 1.38B 0 2024-12
Mettler Toledo International USD 639.31M 66.85M 2024-12
Myriad Genetics USD 150.9M 1.1M 2024-12
Patterson Companies USD 320.82M 7.27M 2025-01
Pfizer USD 12.11B 718M 2024-12
Repligen USD 77.49M 220K 2024-09
Revvity USD 412.29M 27.47M 2024-12
Standard Biotools USD 21.9M 1.36M 2024-12
Thermo Fisher Scientific USD 4.82B 494M 2024-12
Waters USD 524.2M 85.55M 2024-12
West Pharmaceutical Services USD 273.6M 8.9M 2024-12



Repligen Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.